Abstract: OBJECTIVE To explore the safety risk of bimaprost for eyelash growth. METHODS The physical and chemical properties, pharmacological effects, pharmacokinetics, clinical application, adverse reaction and cosmetic regulatory policy of bimaprost were combed and analyzed in order to provide a theoretical basis for supervision. RESULTS Bimaprost was a synthetic prostaglandin analogue-prostaglandin F_2α, which could effectively reduce intraocular pressure and promote hair/eyelash growth. The elimination half-life of bimaprost was 45 min and was mainly excreted through urine. Bimatoprost had a FDA rating of C during pregnancy, which might have an adverse effect on the fetus. The adverse reactions of bimaprost after listing mainly include eye hyperemia, eyelid erythema, eye irritation and so on. It was necessary to further evaluates its safety. Bimaprost did not conform to the cosmetic definition, efficacy and claims of China. The European Union and Canada prohibited the use of drug ingredients such as bimaprost in cosmetics, and the United States regulated it as a drug. CONCLUSION In order to ensure the quality and safety of cosmetics, standardize and promote the healthy development of the industry, it is suggested that the regulatory departments of China should follow up and pay attention to the safety of the use of prostaglandin analogs such as bimatoprost and adjust management measures if necessary.